A Pharmacodynamic Comparison Study of Different Botulinum Toxin Type A Preparations

Kim, Sung-Beom; Ban, Bhupal; Jung, Kyoung-Sim; Yang, Gi-Hyeok

doi:10.1111/dsu.12070

Cited by 13 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So in our study, in children, respectively 10-30 units/kg body weight abobotulinum or 2,5-10 units /kg body weight of onabotulinum were used. [33][34][35][36][37][40][41][42][43][44][45][46][47][48][49][50] Estimating the optimal dosage both in children and adolescents is still discussed. Some authors show, both for abobotulinum or onabotulinum, no clear dose-related effect with the observation indicating that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo.…”

Section: Resultsmentioning

confidence: 99%

The endoscopic Botulinum toxin-A injections in equally efficient in the treatment of neurogenic bladder dysfunctions in children in different age groups. Single centre experience after more than 550 procedures.

Kroll¹,

Gajewska²,

Kasprowicz³

et al. 2018

Preprint

View full text Add to dashboard Cite

The aim of this study was to evaluate the usefulness of cystoscopic injection of Botulinum-A toxin (BTX) in the detrusor wall in the treatment of children with decreased bladder capacity due to neurogenic bladder. The prospective, randomized non placebo controlled trial is conducted in our institution since year 2006 with the approval of the local Ethics Committee. 556 cystoscopic injections of BTX were performed in 141 children with neurogenic bladder in age 1 to 18 years. In all cases decreased bladder capacity and bladder overactivity with urine incontinence were estimated. The pre-and post-treatment evaluations included determination of urinary continence status, bladder function in frequency/volume chart of catheterized urine and in urodynamic studies. Parameters measured in urodynamic investigations included maximal cystometric capacity, detrusor reflex volume, maximal detrusor pressure. Parameters were analyzed before the cystoscopy and during the follow-up examinations in 5 age groups. Values of all measured parameters improved significantly and equally after therapy in every from 5 age groups. The results obtained from the study confirmed that endoscopic administration of BTX improves function of urinary bladder in children with neurogenic bladder, and the method represents an alternative approach to conservative treatment and surgical augmentation.

show abstract

Section: Resultsmentioning

confidence: 99%

The endoscopic Botulinum toxin-A injections in equally efficient in the treatment of neurogenic bladder dysfunctions in children in different age groups. Single centre experience after more than 550 procedures.

Kroll¹,

Gajewska²,

Kasprowicz³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…This kind of treatment provides doctors with a conservative nonsurgical therapy. There are 5 types of BTA available on the market: onabotulinum toxin А (BOTOX, Allergan Inc., Irvine, СА, САЩ), abotulinum toxin А (Dysport, Ipsen Limited, Wrexham, UK), BTXA (Prosigne, Lanzhou Institute, China), incobutinum toxin А (Xeomin, Mers Pharmaceuticals, Franfurkt AM Main, Germany), and Neuronox (Medytox Inc., Cheonwon-gun, South Corea) (18,19). In literature some authors try to achieve muscle atrophy by secondary application of the toxin following patient requests but others recommend monthly applications of the toxin until suppressing muscle activity with frequent additional doses to stop the recovery of the muscle force by more than 30%.…”

Section: Application Of Botulinum Toxin Type a (Bta)mentioning

confidence: 99%

Mаsseter Muscle Hypertrophy in Dentistry

Vasileva

2018

Scripta Scientifica Medicinae Dentalis

View full text Add to dashboard Cite

Masseter hypertrophy (MH) is rare, asymptomatic condition with unexplained etiology. The main finding is unilateral or bilateral benign enlargement of masseter muscles, which results in a pronounced contour of the face and/or in the angle of the lower jaw, as well as the occurrence of asymmetry in unilateral hypertrophy. Surgical resection of the masseter was a conventional method in the past for asymmetric edema treatment above the shoulder and the angle of the lower jaw, after unsuccessful altering of the vertical dimension, dental aligners, tranquilizers, etc. An effective alternative is injecting locally small doses of botulin toxin type A in the masseter. The toxin prevents the release of acetylcholine, causing presynaptic neuromuscular blockage. This way the muscles could be selectively weakened and after local paralysis muscle atrophy is observed. This technique ensures predictable result and it is an alternative conservative method for treating this type facial asymmetry. Another conservative way for treating MH is radio frequency electrocoagulation. The presence of MH after dental treatment requires specialized intervention of specialists and application of contemporary non-invasive interventions with predictable results.

show abstract

“…Five botulinum toxin type A preparations are commercially available: onabotulinum toxin A (BOTOX, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (Dysport, Ipsen Limited, Wrexham, UK), BTXA (Prosigne, Lanzhou Institute, Lanzhou, China), incobotulinum toxin A (Xeomin, Mers Pharmaceuticals, Frankfurt AM Main, Germany), and Neuronox (Medytox Inc., Cheonwon-gun, South Korea). 23 Previous studies on the use of botulinum toxin type A for the treatment of masseter hypertrophy have used different preparations and different dosages. This lack of standardization hampers the comparison between studies.…”

Section: Introductionmentioning

confidence: 99%

Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy

Klein¹,

Brenner

Sato

et al. 2014

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUNDMasseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians.OBJECTIVESThe goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy treatment in Brazilians.METHODSTen Brazilian female patients with masseter hypertrophy were subjected to injections of 90U of abobotulinum toxin A applied on each side respecting the safety zone stabilished in literature and were followed up for 24 weeks.RESULTSWhen analyzing the coefficients between measures of middle and lower third of the face obtained from standardized photographs, an increase was observed, with statistical significance at 2 weeks (p=0.005) and 12 weeks (p=0.001). The progression of lower third reduction was 3.94%, 5.26%, 11.99%, and 5.47% (2, 4, 12, and 24 weeks respectively). All patients showed improvement in bruxism after treatment. Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry.CONCLUSIONThe use of abobotulinum toxin A for masseter hypertrophy is effective in Brazilians and reached its maximum effect of facial thinning at 12 weeks. Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination. Despite its side effects, 80% of the patients would like to repeat the treatment.

show abstract

A Pharmacodynamic Comparison Study of Different Botulinum Toxin Type A Preparations

Abstract: Neu-BoNT/A and ona-BoNT/A may be interchangeable based on a simple dose ratio.

Cited by 13 publications

References 9 publications

The endoscopic Botulinum toxin-A injections in equally efficient in the treatment of neurogenic bladder dysfunctions in children in different age groups. Single centre experience after more than 550 procedures.

The endoscopic Botulinum toxin-A injections in equally efficient in the treatment of neurogenic bladder dysfunctions in children in different age groups. Single centre experience after more than 550 procedures.

Mаsseter Muscle Hypertrophy in Dentistry

Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy

Contact Info

Product

Resources

About